Research Ethics 9 (3):109-120 (2013)
AbstractDiscussions about the merits and shortcomings of non-inferiority trials are becoming increasingly common in the medical community and among regulatory agencies. However, criticisms targeting the ethical standing of non-inferiority trials have often been mistargeted. In this article we review the ethical standing of trials of non-inferiority. In the first part of the article, we outline a consequentialist position according to which clinical trials are best conceived as epistemic tools aimed at fostering the proper ends of medicine. According to this view, clinical trials are means to ends, and thus their moral status depends both on how well they perform as means to reach desired ends and on which ends they are meant to achieve. Building upon this normative framework in the next two sections we analyze the specific ethical issues raised by non-inferiority trials. By making it clear that clinical trials are just epistemic tools – i.e. means to certain ends – it is possible not only to clarify the conceptual debate over a fundamental issue in clinical research, but also to identify which ethically relevant considerations ought to be addressed in setting up a non-inferiority trial
Similar books and articles
Clinical Trials: Active Control Vs Placebo — What is Ethical?Jacek Spławiński & Jerzy Kuźniar - 2004 - Science and Engineering Ethics 10 (1):73-79.
The Research Misconception.Maurie Markman - 2004 - International Journal of Applied Philosophy 18 (2):241-252.
Uncertainty and the Ethics of Clinical Trials.Sven Ove Hansson - 2006 - Theoretical Medicine and Bioethics 27 (2):149-167.
What Makes Placebo-Controlled Trials Unethical?Franklin G. Miller & Howard Brody - 2002 - American Journal of Bioethics 2 (2):3 – 9.
Monitoring in Clinical Trials: Benefit or Bias?Cecilia Nardini - 2013 - Theoretical Medicine and Bioethics 34 (4):259-274.
Using Empirical Data to Inform the Ethical Evaluation of Placebo Controlled Trials.Jeremy Sugarman - 2004 - Science and Engineering Ethics 10 (1):29-35.
The Protection of Patients' Rights in Clinical Trials.Marek Czarkowski - 2006 - Science and Engineering Ethics 12 (1):131-138.
Are Explanatory Trials Ethical? Shifting the Burden of Justification in Clinical Trial Design.Kirstin Borgerson - 2013 - Theoretical Medicine and Bioethics 34 (4):293-308.
Are Phase 1 Trials Therapeutic? Risk, Ethics, and Division of Labor.James A. Anderson & Jonathan Kimmelman - 2014 - Bioethics 28 (3):138-146.
Placebos and the UK Medical Research Council — and the Consumer Perspective.Joan Box - 2004 - Science and Engineering Ethics 10 (1):95-101.
Evaluating the First-in-Human Clinical Trial of a Human Embryonic Stem Cell-Based Therapy.Audrey R. Chapman & Courtney C. Scala - 2012 - Kennedy Institute of Ethics Journal 22 (3):243-261.
Bayesian Versus Frequentist Clinical Trials.David Teira - 2011 - In Gifford Fred (ed.), Philosophy of Medicine. Amsterdam: Elsevier. pp. 255-297.
End of Life Pediatric Research: What About the Ethics? [REVIEW]Danielle Laudy - 2009 - Journal of Academic Ethics 7 (1-2):87-91.
Ethical Considerations in Clinical Trials: A Critique of the ICH-GCP Guideline.Sharon Kaur & Choong Yeow Choy - 2012 - Developing World Bioethics 12 (3):20-28.
Added to PP
Historical graph of downloads
Citations of this work
Robustness, Diversity of Evidence, and Probabilistic Independence.Jonah N. Schupbach - 2015 - In Mäki, Ruphy, Schurz & Votsis (eds.), Recent Developments in the Philosophy of Science: EPSA13 Helsinki. Springer. pp. 305-316.
Editorial: Tamiflu and the Open Data Campaign.Sarah Jl Edwards - 2013 - Research Ethics 9 (3):94-96.
References found in this work
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects.World Medical Association - 2009 - Jahrbuch für Wissenschaft Und Ethik 14 (1):233-238.
The Quality of Life.Martha Nussbaum & Amartya Sen - 1993 - Tijdschrift Voor Filosofie 57 (2):377-378.
A Critique of Clinical Equipoise: Therapeutic Misconception in the Ethics of Clinical Trials.Franklin G. Miller & Howard Brody - 2003 - Hastings Center Report 33 (3):19-28.